Pedro E. Lopez, M.D.; Decision and Order, 46324-46326 [2015-19119]
Download as PDF
46324
Federal Register / Vol. 80, No. 149 / Tuesday, August 4, 2015 / Notices
80 FR 22557, Sigma Aldrich Research
Biochemicals, Inc., 1–3 Strathmore
Road, Natick, Massachusetts 01760–
2447 applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of Sigma Aldrich
Research Biochemicals, Inc. to
manufacture the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed:
Controlled substance
Schedule
Cathinone (1235) .........................................................................................................................................................................................
Methcathinone (1237) ..................................................................................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) (1248) ....................................................................................................................................
Aminorex (1585) ..........................................................................................................................................................................................
Alpha-ethyltryptamine (7249) ......................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ..............................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (7392) ..........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ..............................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ....................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) ..................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ............................................................................................................................................
Dimethyltryptamine (7435) ..........................................................................................................................................................................
Psilocybin (7437) .........................................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine (7439) ..............................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ...............................................................................................................................................
N-Benzylpiperazine (7493) ..........................................................................................................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) (7535) .......................................................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) (7540) .......................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Nabilone (7379) ...........................................................................................................................................................................................
1-Phenylcyclohexylamine (7460) .................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Ecgonine (9180) ..........................................................................................................................................................................................
Levomethorphan (9210) ..............................................................................................................................................................................
Levorphanol (9220) .....................................................................................................................................................................................
Meperidine (9230) .......................................................................................................................................................................................
Metazocine (9240) .......................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Levo-alphacetylmethadol (9648) .................................................................................................................................................................
Remifentanil (9739) .....................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Carfentanil (9743) ........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
tkelley on DSK3SPTVN1PROD with NOTICES
The company plans to manufacture
reference standards.
Dated: July 29, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 15–16]
[FR Doc. 2015–19166 Filed 8–3–15; 8:45 am]
BILLING CODE P
Pedro E. Lopez, M.D.; Decision and
Order
On March 20, 2015, Chief
Administrative Law Judge (CALJ) John J.
Mulrooney, II, issued the attached
Recommended Decision. Neither party
VerDate Sep<11>2014
18:45 Aug 03, 2015
Jkt 235001
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
filed exceptions to the Recommended
Decision.
Having reviewed the record in its
entirety, I adopt the CALJ’s findings of
fact,1 conclusions of law, and
1 I take official notice of the fact that, according
to the registration records of the Agency,
Respondent retains an active registration as of this
date. Pursuant to 21 CFR 1316.59(e), Respondent
may controvert this finding by filing a properly
supported motion, no later than 10 days from the
date of this Order.
E:\FR\FM\04AUN1.SGM
04AUN1
Federal Register / Vol. 80, No. 149 / Tuesday, August 4, 2015 / Notices
recommended order. Accordingly, I will
order that Respondent’s DEA Certificate
of Registration be revoked and that any
pending applications to renew or
modify his registration be denied.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 824(a)(3), as
well as 28 CFR 0.100(b), I order that
DEA Certificate of Registration
BL2132049, issued to Pedro E. Lopez,
M.D., be, and it hereby is, revoked. I
further order that any pending
application of Pedro E. Lopez, M.D., to
renew or modify his registration, be, and
it hereby is, denied. This Order is
effective September 3, 2015.
Dated: July 27, 2015.
Chuck Rosenberg,
Acting Administrator.
Brian Bayly, Esq., for the Government.
Alan Rhine, Esq., for the Respondent.
tkelley on DSK3SPTVN1PROD with NOTICES
ORDER GRANTING THE
GOVERNMENT’S MOTION FOR
SUMMARY DISPOSITION AND
RECOMMENDED RULINGS, FINDINGS
OF FACT, CONCLUSIONS OF LAW,
AND DECISION OF THE
ADMINISTRATIVE LAW JUDGE
Chief Administrative Law Judge John
J. Mulrooney, II. The Deputy Assistant
Administrator, Drug Enforcement
Administration (DEA or Government),
issued an Order to Show Cause (OSC),
dated February 6, 2015, proposing to
revoke the DEA Certificate of
Registration (COR), Number BL2132049,
of Pedro E. Lopez, M.D. (Respondent),
pursuant to 21 U.S.C. 824(a)(3) and 21
U.S.C. 823(f), and deny any pending
applications for renewal or modification
of the COR, pursuant to 21 U.S.C. 823(f).
In the OSC, the Government alleges
that the Respondent is, inter alia,
without ‘‘authority to handle controlled
substances in the State of Illinois’’ as
grounds for revocation of the
Respondent’s DEA registration. On
March 6, 2015, the Respondent, by
counsel, filed a Request for Hearing in
the above-captioned matter. The
Request for Hearing stated that a hearing
Notwithstanding that the language of section
824(a) authorizes either the suspension or
revocation of a registration upon the making of one
of the five findings enumerated therein, the Agency
has consistently interpreted the CSA as mandating
revocation where a practitioner’s state authority has
been suspended or revoked. As the Fourth Circuit
has held, ‘‘[b]ecause § 823(f) and § 802(21) make
clear that a practitioner’s registration is dependent
upon the practitioner having state authority to
dispense controlled substances, the
[Administrator’s] decision to construe § 824(a)(3) as
mandating revocation upon suspension of a state
license is not an unreasonable interpretation of the
CSA.’’ Hooper v. Holder, 2012 WL 2020079, *2 (4th
Cir. 2012) (unpublished).
VerDate Sep<11>2014
18:45 Aug 03, 2015
Jkt 235001
is appropriate because ‘‘the Respondent
has instituted proceedings to restore his
authority to handle controlled
substances in Illinois.’’ Req. for Hrg. at
1.
Consistent with my direction, the
parties have briefed the issues. On
March 11, 2015, the Government filed a
Motion for Summary Disposition and
Evidence in Support of its Motion for
Summary Disposition (Motion for
Summary Disposition), seeking that this
tribunal issue a Recommended Decision
granting the Government’s Motion on
the ground that the Respondent is
currently without state authority to
handle controlled substances. Mot. for
Summary Disp. at 1. According to the
Government’s Motion, the State of
Illinois, Department of Financial and
Professional Regulation (IDFPR)
suspended the Respondent’s license to
practice medicine, effective March 12,
2014, and that suspension order remains
in effect. Id. Attached to the
Government’s Motion is the IDFPR
Order dated March 12, 2014 suspending
the Respondent’s state Physician and
Surgeon License No. 036.074815 on the
grounds that the Respondent failed to
comply with the provisions an
Agreement of Care, Counseling and
Treatment that he had entered into with
IDFPR.2 Id., Attachment 1 at
1–2. Under the IDPFR Order, the
Respondent’s state license was
indefinitely suspended for a minimum
period of six months. Id., Attachment 1
at 2.
On March 20, 2015, the Respondent,
through counsel, filed a reply styled
‘‘Response to the Government’s Motion
for Summary Disposition and Evidence
in Support of its Motion for Summary
Disposition’’ (Respondent’s Reply). In
his Reply, the Respondent alleges that
he is in the process of seeking
reinstatement of his medical license
from the state of Illinois. Resp’t Reply at
2. In opposing the Government’s
requested relief, the Respondent avers
that inasmuch as he is currently not
prescribing controlled substances,
granting a hearing, or at least deferring
adjudication until his state privileges
are restored presents no cognizable
danger to the public. Id. at 2–3.
In order to revoke a registrant’s DEA
registration, the DEA has the burden of
proving that the requirements for
revocation are satisfied. 21 CFR
1301.44(e) (2015). Once DEA has made
its prima facie case for revocation of the
registrant’s DEA COR, the burden of
2 No objection to consideration of the
Government’s exhibit, or factual challenge to the
matters asserted therein was asserted by the
Respondent.
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
46325
production then shifts to the
Respondent to show that, given the
totality of the facts and circumstances in
the record, revoking the registrant’s
registration would not be appropriate.
Morall v. DEA, 412 F.3d 165, 174 (D.C.
Cir. 2005); Humphreys v. DEA, 96 F.3d
658, 661 (3d Cir. 1996); Shatz v. U.S.
Dept. of Justice, 873 F.2d 1089, 1091
(8th Cir. 1989); Thomas E. Johnston, 45
FR 72311 (1980).
The Controlled Substances Act (CSA)
requires that, in order to maintain a
DEA registration, a practitioner must be
authorized to handle controlled
substances in ‘‘the jurisdiction in which
he practices.’’ See 21 U.S.C. 802(21)
(2012) (‘‘[t]he term ‘practitioner’ means
a physician . . . licensed, registered, or
otherwise permitted, by . . . the
jurisdiction in which he practices . . .
to distribute, dispense, [or] administer
. . . a controlled substance in the
course of professional practice’’); see
also 21 U.S.C. 823(f) (2012) (‘‘The
Attorney General shall register
practitioners . . . if the applicant is
authorized to dispense . . . controlled
substances under the laws of the State
in which he practices.’’). DEA has long
held that possession of authority under
state law to dispense controlled
substances is an essential condition for
obtaining and maintaining a DEA
´
registration. Serenity Cafe, 77 FR 35027,
35028 (2012); David W. Wang, 72 FR
54297, 54298 (2007); Sheran Arden
Yeates, 71 FR 39130, 39131 (2006);
Dominick A. Ricci, M.D., 58 FR 51104
(1993); Bobby Watts, M.D., 53 FR 11919
(1988). Because ‘‘possessing authority
under state law to handle controlled
substances is an essential condition for
holding a DEA registration,’’ this
Agency has consistently held that ‘‘the
CSA requires the revocation of a
registration issued to a practitioner who
lacks [such authority].’’ Roy Chi Lung,
74 FR 20346, 20347 (2009); see also
Scott Sandarg, D.M.D., 74 FR 17528,
174529 (2009); John B. Freitas, D.O., 74
FR 17524, 17525 (2009); Roger A.
Rodriguez, M.D., 70 FR 33206, 33207
(2005); Stephen J. Graham, M.D., 69 FR
11661 (2004); Abraham A. Chaplan,
M.D., 57 FR 55280 (1992); see also
Harrell E. Robinson, 74 FR 61370, 61375
(2009).3 ‘‘[R]evocation is warranted even
where a practitioner’s state authority
has been summarily suspended and the
State has yet to provide the practitioner
3 But see 21 U.S.C. 824(a)(3) (2012) (‘‘A
registration pursuant to section 823 of this title to
manufacture, distribute, or dispense a controlled
substance may be suspended or revoked by the
Attorney General upon a finding that the registrant
. . . has had his State license or registration
suspended, revoked, or denied by competent State
authority . . . .’’) (emphasis added).
E:\FR\FM\04AUN1.SGM
04AUN1
46326
Federal Register / Vol. 80, No. 149 / Tuesday, August 4, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
with a hearing to challenge the State’s
action at which he may ultimately
prevail.’’ Kamal Tiwari, M.D., 76 FR
71604, 71606, (2011); see also Bourne
Pharmacy, Inc., 72 FR 18273, 18274
(2007); Anne Lazar Thorn, 62 FR 12847
(1997). Additionally, Agency precedent
has established that the existence of
other proceedings in which the
Respondent is involved is not a basis
upon which to justify a stay of DEA
administrative enforcement
proceedings. Grider Drug #1 & Grider
Drug #2, 77 FR 44069, 44104 n.97
(2012).
Congress does not intend for
administrative agencies to perform
meaningless tasks. See Philip E. Kirk,
M.D., 48 FR 32887 (1983), aff’d sub
nom. Kirk v. Mullen, 749 F.2d 297 (6th
Cir. 1984); see also Puerto Rico
Aqueduct & Sewer Auth. v. EPA, 35
F.3d 600, 605 (1st Cir. 1994); NLRB v.
Int’l Assoc. of Bridge, Structural &
Ornamental Ironworkers, AFL–CIO, 549
F.2d 634 (9th Cir. 1977); United States
v. Consol. Mines & Smelting Co., 455
F.2d 432, 453 (9th Cir. 1971). Thus, it
is well-settled that, where no genuine
question of fact is involved, or when the
material facts are agreed upon, a
plenary, adversarial administrative
proceeding is not required. See Jesus R.
Juarez, M.D., 62 FR 14945 (1997);
Dominick A. Ricci, M.D., 58 FR 51104
(1993). Here, the supplied IDFPR Order
establishes, and the Respondent does
not contest, that the Respondent is
currently without authorization to
handle controlled substances in Illinois,
the jurisdiction where the Respondent
holds the DEA COR that is the subject
of this litigation.
Summary disposition of an
administrative case is warranted where,
as here, ‘‘there is no factual dispute of
substance.’’ See Veg-Mix, Inc., 832 F.2d
601, 607 (D.C. Cir. 1987) (‘‘an agency
may ordinarily dispense with a hearing
when no genuine dispute exists’’).4 At
this juncture, no genuine dispute exists
over the fact that the Respondent lacks
state authority to handle controlled
substances in the state of Illinois.
Because the Respondent lacks such state
authority, both the plain language of
applicable federal statutory provisions
and Agency interpretive precedent
dictate that the Respondent is not
entitled to maintain his DEA
4 Even assuming, arguendo, the possibility that
the Respondent’s state controlled substances
privileges could be reinstated, summary disposition
would still be warranted because ‘‘revocation is also
appropriate when a state license has been
suspended, but with the possibility of future
reinstatement,’’ Rodriguez, 70 FR at 33207 (citations
omitted), and even where there is a judicial
challenge to the state medical board action actively
VerDate Sep<11>2014
18:45 Aug 03, 2015
Jkt 235001
registration. Simply put, there is no
contested factual matter adducible at a
hearing that would provide DEA with
the authority to allow the Respondent to
continue to hold his COR.
Accordingly, I hereby
GRANT the Government’s Motion for
Summary Disposition; and further
DENY the Respondent’s Request for
Stay; and further
RECOMMEND that the Respondent’s
DEA registration be REVOKED forthwith
and any pending applications for
renewal be DENIED.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Manufacturer of Controlled
Substances Registration: National
Center for Natural Products Research
(NIDA MPROJECT), Inc.
ACTION:
Notice of registration.
BILLING CODE 4410–09–P
National Center for Natural
Products Research (NIDA MPROJECT),
Inc. applied to be registered as a
manufacturer of certain basic classes of
controlled substances. The Drug
Enforcement Administration (DEA)
grants National Center for Natural
Products Research (NIDA MPROJECT),
Inc. registration as a manufacturer of
those controlled substances.
SUPPLEMENTARY INFORMATION: By notice
dated April 14, 2015, and published in
the Federal Register on April 22, 2015,
80 FR 22559, National Center for
Natural Products Research (NIDA
MPROJECT), Inc., University of
Mississippi, 135 Coy Waller Complex,
University, Mississippi 38677–1848
applied to be registered as a
manufacturer of certain basic classes of
controlled substances. No comments or
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of National Center for
Natural Products Research (NIDA
MPROJECT), Inc. to manufacture the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above-named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances:
pending in the state courts. Michael G. Dolin, M.D.,
65 FR 5661, 5662 (2000).
1 After both the Administrator’s Order and the
Government’s Response were returned to the
Agency as undelivered following efforts to serve
both of Respondent’s counsels, the Government
determined through the New York State Unified
Court System’s database that each attorney had a
different address than that listed in the record.
Notice of Recent Order and Government’s Response
II, at 1–2. The Government represents that on June
30, 2015, it served both the Administrator’s Order
and its Response on each of Respondent’s attorneys
by mailing them to the addresses of Respondent’s
attorneys as listed in the New York Unified Court
System’s database. Id. at 2.
Dated: March 20, 2015.
JOHN J. MULROONEY, II,
Chief Administrative Law Judge.
[FR Doc. 2015–19119 Filed 8–3–15; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 12–49]
AIM Pharmacy & Surgical S. Corp.
Order
On May 8, 2015, the Administrator of
the Drug Enforcement Administration,
noting that the expiration date of
Respondent’s registration was June 30,
2014, ordered the parties to address
whether the case is now moot. The
Administrator’s Order was served on
Respondent’s counsel at his address of
record.
The Government filed a timely
response and served a copy of its
response on Respondent’s counsel at his
address of record. Govt. Response to
Administrator’s May 8, 2015 Order, at 1.
Respondent has not filed a response.1
In its Response, the Government
advises that Respondent neither
submitted a renewal application prior to
the expiration of its registration nor an
application for a new registration. Id.
The Government therefore
acknowledges that this case is now
moot. Id.; see Ronald J. Riegel, 63 FR
67132, 67133 (1998). Accordingly, I
dismiss the Order to Show Cause.
It is so ordered.
Date: July 27, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–19116 Filed 8–3–15; 8:45 am]
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
SUMMARY:
E:\FR\FM\04AUN1.SGM
04AUN1
Agencies
[Federal Register Volume 80, Number 149 (Tuesday, August 4, 2015)]
[Notices]
[Pages 46324-46326]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-19119]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 15-16]
Pedro E. Lopez, M.D.; Decision and Order
On March 20, 2015, Chief Administrative Law Judge (CALJ) John J.
Mulrooney, II, issued the attached Recommended Decision. Neither party
filed exceptions to the Recommended Decision.
Having reviewed the record in its entirety, I adopt the CALJ's
findings of fact,\1\ conclusions of law, and
[[Page 46325]]
recommended order. Accordingly, I will order that Respondent's DEA
Certificate of Registration be revoked and that any pending
applications to renew or modify his registration be denied.
---------------------------------------------------------------------------
\1\ I take official notice of the fact that, according to the
registration records of the Agency, Respondent retains an active
registration as of this date. Pursuant to 21 CFR 1316.59(e),
Respondent may controvert this finding by filing a properly
supported motion, no later than 10 days from the date of this Order.
Notwithstanding that the language of section 824(a) authorizes
either the suspension or revocation of a registration upon the
making of one of the five findings enumerated therein, the Agency
has consistently interpreted the CSA as mandating revocation where a
practitioner's state authority has been suspended or revoked. As the
Fourth Circuit has held, ``[b]ecause Sec. 823(f) and Sec. 802(21)
make clear that a practitioner's registration is dependent upon the
practitioner having state authority to dispense controlled
substances, the [Administrator's] decision to construe Sec.
824(a)(3) as mandating revocation upon suspension of a state license
is not an unreasonable interpretation of the CSA.'' Hooper v.
Holder, 2012 WL 2020079, *2 (4th Cir. 2012) (unpublished).
---------------------------------------------------------------------------
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f) and
824(a)(3), as well as 28 CFR 0.100(b), I order that DEA Certificate of
Registration BL2132049, issued to Pedro E. Lopez, M.D., be, and it
hereby is, revoked. I further order that any pending application of
Pedro E. Lopez, M.D., to renew or modify his registration, be, and it
hereby is, denied. This Order is effective September 3, 2015.
Dated: July 27, 2015.
Chuck Rosenberg,
Acting Administrator.
Brian Bayly, Esq., for the Government.
Alan Rhine, Esq., for the Respondent.
ORDER GRANTING THE GOVERNMENT'S MOTION FOR SUMMARY DISPOSITION AND
RECOMMENDED RULINGS, FINDINGS OF FACT, CONCLUSIONS OF LAW, AND DECISION
OF THE ADMINISTRATIVE LAW JUDGE
Chief Administrative Law Judge John J. Mulrooney, II. The Deputy
Assistant Administrator, Drug Enforcement Administration (DEA or
Government), issued an Order to Show Cause (OSC), dated February 6,
2015, proposing to revoke the DEA Certificate of Registration (COR),
Number BL2132049, of Pedro E. Lopez, M.D. (Respondent), pursuant to 21
U.S.C. 824(a)(3) and 21 U.S.C. 823(f), and deny any pending
applications for renewal or modification of the COR, pursuant to 21
U.S.C. 823(f).
In the OSC, the Government alleges that the Respondent is, inter
alia, without ``authority to handle controlled substances in the State
of Illinois'' as grounds for revocation of the Respondent's DEA
registration. On March 6, 2015, the Respondent, by counsel, filed a
Request for Hearing in the above-captioned matter. The Request for
Hearing stated that a hearing is appropriate because ``the Respondent
has instituted proceedings to restore his authority to handle
controlled substances in Illinois.'' Req. for Hrg. at 1.
Consistent with my direction, the parties have briefed the issues.
On March 11, 2015, the Government filed a Motion for Summary
Disposition and Evidence in Support of its Motion for Summary
Disposition (Motion for Summary Disposition), seeking that this
tribunal issue a Recommended Decision granting the Government's Motion
on the ground that the Respondent is currently without state authority
to handle controlled substances. Mot. for Summary Disp. at 1. According
to the Government's Motion, the State of Illinois, Department of
Financial and Professional Regulation (IDFPR) suspended the
Respondent's license to practice medicine, effective March 12, 2014,
and that suspension order remains in effect. Id. Attached to the
Government's Motion is the IDFPR Order dated March 12, 2014 suspending
the Respondent's state Physician and Surgeon License No. 036.074815 on
the grounds that the Respondent failed to comply with the provisions an
Agreement of Care, Counseling and Treatment that he had entered into
with IDFPR.\2\ Id., Attachment 1 at 1-2. Under the IDPFR Order, the
Respondent's state license was indefinitely suspended for a minimum
period of six months. Id., Attachment 1 at 2.
---------------------------------------------------------------------------
\2\ No objection to consideration of the Government's exhibit,
or factual challenge to the matters asserted therein was asserted by
the Respondent.
---------------------------------------------------------------------------
On March 20, 2015, the Respondent, through counsel, filed a reply
styled ``Response to the Government's Motion for Summary Disposition
and Evidence in Support of its Motion for Summary Disposition''
(Respondent's Reply). In his Reply, the Respondent alleges that he is
in the process of seeking reinstatement of his medical license from the
state of Illinois. Resp't Reply at 2. In opposing the Government's
requested relief, the Respondent avers that inasmuch as he is currently
not prescribing controlled substances, granting a hearing, or at least
deferring adjudication until his state privileges are restored presents
no cognizable danger to the public. Id. at 2-3.
In order to revoke a registrant's DEA registration, the DEA has the
burden of proving that the requirements for revocation are satisfied.
21 CFR 1301.44(e) (2015). Once DEA has made its prima facie case for
revocation of the registrant's DEA COR, the burden of production then
shifts to the Respondent to show that, given the totality of the facts
and circumstances in the record, revoking the registrant's registration
would not be appropriate. Morall v. DEA, 412 F.3d 165, 174 (D.C. Cir.
2005); Humphreys v. DEA, 96 F.3d 658, 661 (3d Cir. 1996); Shatz v. U.S.
Dept. of Justice, 873 F.2d 1089, 1091 (8th Cir. 1989); Thomas E.
Johnston, 45 FR 72311 (1980).
The Controlled Substances Act (CSA) requires that, in order to
maintain a DEA registration, a practitioner must be authorized to
handle controlled substances in ``the jurisdiction in which he
practices.'' See 21 U.S.C. 802(21) (2012) (``[t]he term `practitioner'
means a physician . . . licensed, registered, or otherwise permitted,
by . . . the jurisdiction in which he practices . . . to distribute,
dispense, [or] administer . . . a controlled substance in the course of
professional practice''); see also 21 U.S.C. 823(f) (2012) (``The
Attorney General shall register practitioners . . . if the applicant is
authorized to dispense . . . controlled substances under the laws of
the State in which he practices.''). DEA has long held that possession
of authority under state law to dispense controlled substances is an
essential condition for obtaining and maintaining a DEA registration.
Serenity Caf[eacute], 77 FR 35027, 35028 (2012); David W. Wang, 72 FR
54297, 54298 (2007); Sheran Arden Yeates, 71 FR 39130, 39131 (2006);
Dominick A. Ricci, M.D., 58 FR 51104 (1993); Bobby Watts, M.D., 53 FR
11919 (1988). Because ``possessing authority under state law to handle
controlled substances is an essential condition for holding a DEA
registration,'' this Agency has consistently held that ``the CSA
requires the revocation of a registration issued to a practitioner who
lacks [such authority].'' Roy Chi Lung, 74 FR 20346, 20347 (2009); see
also Scott Sandarg, D.M.D., 74 FR 17528, 174529 (2009); John B.
Freitas, D.O., 74 FR 17524, 17525 (2009); Roger A. Rodriguez, M.D., 70
FR 33206, 33207 (2005); Stephen J. Graham, M.D., 69 FR 11661 (2004);
Abraham A. Chaplan, M.D., 57 FR 55280 (1992); see also Harrell E.
Robinson, 74 FR 61370, 61375 (2009).\3\ ``[R]evocation is warranted
even where a practitioner's state authority has been summarily
suspended and the State has yet to provide the practitioner
[[Page 46326]]
with a hearing to challenge the State's action at which he may
ultimately prevail.'' Kamal Tiwari, M.D., 76 FR 71604, 71606, (2011);
see also Bourne Pharmacy, Inc., 72 FR 18273, 18274 (2007); Anne Lazar
Thorn, 62 FR 12847 (1997). Additionally, Agency precedent has
established that the existence of other proceedings in which the
Respondent is involved is not a basis upon which to justify a stay of
DEA administrative enforcement proceedings. Grider Drug #1 & Grider
Drug #2, 77 FR 44069, 44104 n.97 (2012).
---------------------------------------------------------------------------
\3\ But see 21 U.S.C. 824(a)(3) (2012) (``A registration
pursuant to section 823 of this title to manufacture, distribute, or
dispense a controlled substance may be suspended or revoked by the
Attorney General upon a finding that the registrant . . . has had
his State license or registration suspended, revoked, or denied by
competent State authority . . . .'') (emphasis added).
---------------------------------------------------------------------------
Congress does not intend for administrative agencies to perform
meaningless tasks. See Philip E. Kirk, M.D., 48 FR 32887 (1983), aff'd
sub nom. Kirk v. Mullen, 749 F.2d 297 (6th Cir. 1984); see also Puerto
Rico Aqueduct & Sewer Auth. v. EPA, 35 F.3d 600, 605 (1st Cir. 1994);
NLRB v. Int'l Assoc. of Bridge, Structural & Ornamental Ironworkers,
AFL-CIO, 549 F.2d 634 (9th Cir. 1977); United States v. Consol. Mines &
Smelting Co., 455 F.2d 432, 453 (9th Cir. 1971). Thus, it is well-
settled that, where no genuine question of fact is involved, or when
the material facts are agreed upon, a plenary, adversarial
administrative proceeding is not required. See Jesus R. Juarez, M.D.,
62 FR 14945 (1997); Dominick A. Ricci, M.D., 58 FR 51104 (1993). Here,
the supplied IDFPR Order establishes, and the Respondent does not
contest, that the Respondent is currently without authorization to
handle controlled substances in Illinois, the jurisdiction where the
Respondent holds the DEA COR that is the subject of this litigation.
Summary disposition of an administrative case is warranted where,
as here, ``there is no factual dispute of substance.'' See Veg-Mix,
Inc., 832 F.2d 601, 607 (D.C. Cir. 1987) (``an agency may ordinarily
dispense with a hearing when no genuine dispute exists'').\4\ At this
juncture, no genuine dispute exists over the fact that the Respondent
lacks state authority to handle controlled substances in the state of
Illinois. Because the Respondent lacks such state authority, both the
plain language of applicable federal statutory provisions and Agency
interpretive precedent dictate that the Respondent is not entitled to
maintain his DEA registration. Simply put, there is no contested
factual matter adducible at a hearing that would provide DEA with the
authority to allow the Respondent to continue to hold his COR.
---------------------------------------------------------------------------
\4\ Even assuming, arguendo, the possibility that the
Respondent's state controlled substances privileges could be
reinstated, summary disposition would still be warranted because
``revocation is also appropriate when a state license has been
suspended, but with the possibility of future reinstatement,''
Rodriguez, 70 FR at 33207 (citations omitted), and even where there
is a judicial challenge to the state medical board action actively
pending in the state courts. Michael G. Dolin, M.D., 65 FR 5661,
5662 (2000).
---------------------------------------------------------------------------
Accordingly, I hereby
GRANT the Government's Motion for Summary Disposition; and further
DENY the Respondent's Request for Stay; and further
RECOMMEND that the Respondent's DEA registration be REVOKED
forthwith and any pending applications for renewal be DENIED.
Dated: March 20, 2015.
JOHN J. MULROONEY, II,
Chief Administrative Law Judge.
[FR Doc. 2015-19119 Filed 8-3-15; 8:45 am]
BILLING CODE 4410-09-P